A multicentre, open label, dose escalation, Phase 1 study in patients with unresectable or metastatic melanoma receiving IMP321 (LAG-3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab.
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Eftilagimod alpha (Primary) ; Pembrolizumab
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- Acronyms TACTI-mel
- Sponsors Immutep Limited
- 08 Feb 2018 According to an Immutep media release, interim results were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (2017).
- 08 Feb 2018 According to an Immutep media release, Database Safety Monitoring Board (DSMB) confirmed that the combination of eftilagimod alpha with pembrolizumab is safe and well tolerated at doses up to 30 mg per subcutaneous injection. Company plans to expand this study by six patients at 30 mg of eftilagimod alpha in combination with pembrolizumab starting at cycle one and with a treatment duration of 12 months.
- 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History